Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof

US9187484B2 · kind B2 · utility

Assignees

• Southern Research Institute · US
• THE UAB RESEARCH FOUNDATION · US

Inventors

• Robert A. Galemmo, Jr. · San Francisco, US
• Andrew B. West · Birmingham, US
• Joseph A. Maddry · Birmingham, US
• Subramaniam Ananthan · Birmingham, US
• Ashish Kumar Pathak · Macomb, US
• Jacob Valiyaveettil · Hoover, US

Key dates

• Filing date: May 2, 2013
• Grant date: Nov 17, 2015
• Expiry date: May 2, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Examples of LRRK2 kinase inhibitors are compounds of the formula:or derivatives thereof. An example is 1-(piperidin-1-yl)-2-((3-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)thio)butan-1-one. Particular uses include treating neurodegenerative diseases, cancer, autoimmune diseases and leprosy.